Serina Therapeutics' 2025 net loss widens as R&D expenses jump
Overview
U.S. biotechnology firm's full-year revenue more than doubled from last year, in line analyst expectations
Operating expenses and net loss increased, mainly due to higher R&D and administrative costs
Company initiated Phase 1b trial for SER-252 and secured up to $30 mln in new financing
Outlook
Company did not provide specific financial or operational guidance for 2026
Result Drivers
R&D SPENDING - Higher research and development expenses were driven by increased clinical activity for SER-252, more staff, consultant costs, and outsourced research services
ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher stock-based compensation for new hires and directors, and consulting for public company infrastructure and investor outreach
OTHER INCOME DECLINE - Other income decreased mainly due to a lower gain from changes in warrant liabilities and losses from the sale of a subsidiary
Company press release: ID:nGNX9lcyf2
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Revenue | Meet | $130,000 | $130,000 (2 Analysts) |
FY Net Income |
| -$19.22 mln |
|
FY Income From Operations |
| -$24.02 mln |
|
FY Operating Expenses |
| $24.15 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Serina Therapeutics Inc is $13.00, about 435% above its March 24 closing price of $2.43
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
